



Target Therapy in Cancer Treatment: mPGES-1 and PARP

Finelli, Francesca^{1,*}; Giuzio, Federica²; Catalano, Alessia³; Iacopetta, Domenico⁴; Ceramella, Jessica⁴; Sinicropi, Maria Stefania⁴; Capasso, Anna⁵; Saturnino, Carmela⁶

¹Struttura Complessa UOP-AO "G. Moscati" Avellino, Italy

²International PhD Programme 'Sciences', University of Basilicata, Department of Science, Viale dell'Ateneo Lucano n. 10, 85100 Potenza, Italy

³University of Bari "Aldo Moro", Department of Pharmacy-Drug Sciences, Via Orabona n. 4, 70126 Bari, Italy

⁴University of Calabria, Department of Pharmacy, Health and Nutritional Sciences, 87036 Arcavacata di Rende, Italy

⁵University of Salerno, Department of Pharmacy, Via Giovanni Paolo II n. 132, 84084 Fisciano (SA), Italy

⁶University of Basilicata, Department of Science, Viale dell'Ateneo Lucano n. 10, 85100 Potenza, Italy

*medfinelli@gmail.com

Abstract

Target therapy is an approach focusing on specific protein or signaling pathways. This therapy is directly aimed to a molecular target such as a receptor, growth factor or enzyme in cancer cells. These targets are used by the tumor cells themselves to obtain uncontrolled proliferation, resistance to traditional therapies and to increase the number of blood vessels in the tissue of origin (neo-angiogenesis). A purpose of target therapy may be to counteract the growth and proliferation of cancer cells through the use of drugs or monoclonal antibodies capable of inhibiting the receptor for the epidermal growth factor (EGFR), that is crucial in the process of neo-angiogenesis, protein kinases (PKs), as regulators of cell growth signals and human epidermal growth factor type 2 (HER2), which is essential in stimulating growth and proliferation of cancer cells. Among anticancer drugs, Bevacizumab, a humanised monoclonal antibody produced by recombinant DNA technique, is used for the first-line treatment of metastatic breast cancer, as it inhibits EGFR and the vascular endothelial cell growth factor (VEGF). Abemaciclib, a protein kinase inhibitor drug, is also used for the treatment of the same cancer. In 20-30% of primary breast tumors, the excessive expression of HER2 is observed; thus, HER2 inhibitors may represent another plausible therapy. A potent HER2 inhibitor is the recombinant humanized IgG1 monoclonal antibody Trastuzumab, which was first tested in 1992 and is currently used for the treatment of HER2 positive breast cancer. Unfortunately, despite the numerous advances in finding new therapies, patients treated with these drugs often suffer from severe undesirable side effects. Therefore, the search for new therapeutic targets may be desirable. In this paper we analyse particularly two targets studied quite recently: the microsomal prostaglandin E2 synthase type 1 (mPGES-1) and poly (ADP-ribose) polymerase (PARP) proteins.

Keywords: mPGES-1, PARP, cancer, tumor, target, mPGES-1 inhibitors, PARP-1 inhibitors.

Introduction

Several studies have been recently carried out on new therapeutic targets in anticancer therapy, which can be added to the existing ones [1-5]. Different targets were studied in the past for antitumor agents, both synthetic [6-10] and natural [11,12]. Complexes with transition metals [13-16], lanthanides and actinides are widely described in the literature as antitumor agents [17,18]. However, cancer therapies are often responsible of side effects, including cardiac effects, such as cardiotoxicity and arrhythmia; hyperkeratotic skin; gonadotoxicity; nausea; vomiting; diarrhoea; bone marrow suppression [19]. Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy [20,21]. Bevacizumab is a humanised monoclonal antibody produced by recombinant DNA technique in Chinese hamster ovary cells that inhibits epidermal growth factor (EGFR). Initially approved for treatment of metastatic colorectal cancer in combination with chemotherapy, its indications now include metastatic breast cancer, non-small-cell lung cancer, glioblastoma, renal cell carcinoma, ovarian cancer and cervical cancer. Bevacizumab, by binding to vascular endothelial cell growth factor (VEGF), prevents the latter from binding to its receptors on the surface of endothelial cells. The inhibition of VEGF will consequently regress the vascularity of the tumors [22]. A protein kinase inhibitor drug used in the treatment of breast cancer is Abemaciclib. It is used for the treatment of metastatic breast cancer [23]. It is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). It inhibits retinoblastoma (Rb) protein phosphorylation and blocks cell cycle progression from G1 to S phase, thus suppressing tumor growth. Thymidylate synthase (TS) is a major target for the design of chemotherapeutic agents and represent a target for the treatment of epithelial-to-mesenchymal transition in non-small cell lung cancer [24,25]. Among protein kinases, targeting tyrosine kinase represent an interesting strategy. Sunitinib is a third-generation tyrosine kinase inhibitor that blocks VEGF receptors. It is used in many cancer diseases, including gastrointestinal stromal tumors, advanced renal cell carcinoma, and progressive, well-differentiated pancreatic neuroendocrine

tumors [26]. Finally, excessive expression of HER2 is observed in 20-30% of primary breast tumors. Trastuzumab, a potent HER2 inhibitor, was tested in 1992 and is currently used in the treatment of HER2 positive breast cancer, also during pregnancy. It is a recombinant humanized IgG1 monoclonal antibody that binds to HER2 subdomain IV and inhibits the proliferation of tumor cells expressing this growth factor [27]. However, all these drugs are not devoid of toxicity. Thus, searches for new targets are ongoing. One target may be represented by microsomal prostaglandin E2 synthase type 1 (mPGES-1), the main source of prostaglandin E2 (PGE2). The other targets are poly (ADP-ribose) polymerase (PARP), which are proteins that catalyze the reaction of poly (ADP-ribosyl) action activated by DNA strand breaks. PGE2 is known as a key mediator of the inflammatory response. However, a new role of PGE2 has been also demonstrated, *i.e.* it induces the proliferation and growth of cancer cells [28]. mPGES-1 is involved in cancers and inflammatory diseases [29]. Recently, it has been suggested as a potential target of newly identified coronavirus disease 2019 (COVID-19) [30-32]. Understanding the function of polyADP-ribosylation *in vivo* was greatly advanced using *Drosophila melanogaster* [33,34]. Clinical interest in PARP-1 has increased over the past decade with the recognition of its roles in transcription regulation, DNA repair, epigenetic bookmarking, and chromatin restructuring [35].

mPGES-1

Human mPGES-1 was cloned by PCR (polymerase chain reaction) from a placenta cDNA library, while its enzymatic activity was determined by using an HTRF kit. It consists of the net enzymatic conversion of prostaglandin H2 (PGH2) added in potassium phosphate buffer to PGE2. The molecular structure of mPGES-1 consists of a bundle of four helices that packs together to form a homotrimer. mPGES-1 is a very rigid molecule, stabilized by several interhelix hydrogen bonds. It contains an insert of 20 amino acids between the transmembrane helices I and II and forms a small positively charged domain. This domain consists of two structured rings and a short helix called domain C [28]. Helices II and IV contain pronounced folds determined by the presence of two proline residues (Pro81 and Pro136) that block

the hydrogen bond network of the helix. The helix node II creates a large cytoplasmic cone-shaped cavity in the center of the mPGES-1 trimer. The side chain of Arg73 blocks the connection between the central cavity and the active site. Arg73 residue has two conformations: in the first conformation, it coordinates one of the glutathione (GSH) carboxylate groups and determines a separation of the cavities (Fig. 1A and C). In the alternative orientation, it interacts with the carbonyl of the main Leu69 chain of an adjacent molecule and the solvent structure of the central cavity. The second conformation provides that the pocket of the active site and the central cavity form a continuous surface (Fig. 1B and C). Given the geometric arrangement of the three active sites and the coordination of GSH through the Arg73 residue, an element of cooperativity can be noted. It is noteworthy that Arg73 is only conserved in mPGES-1 and MGST1 from higher vertebrates, so the mechanism related to the conformation of Arg73 will not occur in other members of the MAPEG family. The mPGES-1 requires GSH as an essential cofactor for its activity. The protein was crystallized in the presence of GSH, which binds to the active site of the enzyme defined primarily by TM1 and TM4 for each of the subunits. GSH interacts in a "U-shape" mainly with Arg126, Arg110 and Glu77 of TM4 and His72 of TM1 of another subunit. A model of the open conformation reveals that prostaglandin endoperoxide PGH₂ could enter the fissure defined by TM1 and TM4, allowing for the synthesis of PGE₂ [36]. GSH is coordinated by hydrogen bonds involving the side chains of helices II and IV (Arg73, Asn74, Glu77, His113, Tyr117, Arg126 and Ser127) and the Arg38 side chain of helix. In addition to the hydrogen bonds, the phenolic group of Tyr130 forms a stacking interaction with the peptide gamma bond between the cysteine and the glutamate side chain of the GSH. Domain does not directly contribute to the interaction with the cofactor. The Asp49 side chain forms a salt bridge with Arg126, thus indirectly contributing to the interaction with GSH. The remaining volume of the GSH binding cavity constitutes a small pocket (site of catalytic activity) [28].

Mechanism of interaction of mPGES-1 and GSH

The conversion of PGH₂ to PGE₂ (Fig. 2) by mPGES-1 is GSH-dependent and involves the cleavage of the O-O bond of the endoperoxide and the elimination of the hydrogen C-9 as a proton. Deprotonation involves thiolated glutathione that has been suggested to attack C-9 carbon to produce a thioemiketal intermediate, which spontaneously reorganizes into PGE₂. An alternative may be the attack of glutathione thiolate (nucleophilic) on oxygen endoperoxide C-9, forming a mixed sulphide. The subsequent deprotonation in C-9 and the cleavage of the O-S bond may lead to the formation of PGE₂ and regeneration of glutathione thiolate [37]. New studies carried out on the analysis of the architecture of the active site confirm that α -carboxylate of GSH forms thiolates, through a molecule of crystallographic water firmly bound in the active site. A network of hydrogen bonds is formed from the α -carboxylate fraction of GSH to the thiol group, an ideal position to assist in the deprotonation mechanism during catalysis [38]. The residue of Asp49 may act as a base during the abstraction of the proton, while the primary role of Arg126 is the stabilization of the pK_a for Asp49 and the prevention of the reduction of the intermediate formed [31]. Both the residues are located in the active site and are essential and mutually dependent during catalysis [38].

Key role of mPGES-1 Arg126 residue

The functional role of Arg126 was then examined through mutations of this residue. It was first replaced with a glutamine residue, then with a lysine one, using the site-directed mutagenesis technique. Given that Arg126 and Asp49 participate in an interaction of intermonomeric charge, in the crystalline structure of mPGES-1 the counterpart negatively charged Asp49 was thought to be changed with an asparagine residue. The results obtained lead to understand the key role of the Arg126 residue that totally compromises the functionality of the enzyme. The mutation also causes a reduction of the conversion of PGH₂ into PGF₂ α , rather than in PGE₂ [38].

Another new therapeutic target: PARP

In the last decade an important role in oncological treatments has been assumed by PARP: poly (ADP-ribose polymerase) type 1 (PARP-1) and type 2 (PARP-2), respectively [39]. PARP proteins catalyze the reaction of poly (ADP-ribosyl) action which is activated by DNA strand breaks. PARP (in particular PARP-1 and PARP-2) quickly recognize DNA strand breaks generated by genotoxic agents and once activated, use βNAD^+ as a substrate, hydrolyze it and release nicotinamide (Nam) and a proton (H^+) [40]. Furthermore, PARPs synthesize and catalyze the transfer of ADP-ribose units on amino acid residues such as glutamate, aspartate, arginine, lysine of acceptor proteins, varying their functioning [41]. PARP proteins are involved in several processes including DNA damage repair, cell death mechanisms (apoptosis and necrosis), transcription and chromatin modification/remodeling and have recently been used as new targets in anticancer therapies [42]. PARP-1 and PARP-2 play a dual role: they act as sensors of DNA damage, while, on the other hand, they act as signal transducers to the downstream effectors [40]. The PARP family of proteins is characterized by the presence of a sequence of 50 amino acids called the PARP "signature" [43] which forms the active site of enzymes [40]. The PARP family includes 17 members, firstly divided into 3 subgroups, but later grouped into 5 subfamilies, as follows: DNA-dependent PARPs: they are active during DNA damage and include PARP-1, PARP-2, PARP-3; Tankyrases: they are responsible for protein-protein interactions and divided into Tankyrase-1 and Tankyrase-2; CCCH PARP: proteins that have a domain related to RNA binding and divided into PARP-7, PARP-12 and PARP-13; Macro-PARP: mediate the migration of proteins towards poly sites (ADP-ribosylation) and include PARP-9, PARP-14, PARP-15; Other PARP including PARP-4, PARP-6, PARP-8, PARP-10, PARP-11 and PARP-16 [43].

PARP-1 and Cancer: Involvement in Tumor Hypoxic Response

The lack of oxygen (hypoxia) in the case of tumors generates phenomena of resistance to therapies as it makes the diffusion of chemotherapy and immunotherapy in poorly vascularized areas

more difficult and, at the same time, in the case of radiotherapy, it reduces the synthesis of ROS (Reactive Oxygen Species). The response to this hypoxic condition is important for stabilizing the tumor microenvironment and increasing the volume of the tumor itself. The formation of new vessels supplies the hypoxic tumor with nutrients and oxygen and in this way will favor the growth, proliferation, cellular plasticity, migration and aggressiveness of the neoplastic cells. The hypoxic response occurs following the stabilization of hypoxia inducible factors (HIF). HIF are transcription factors consisting of three chains: HIF1 α , HIF2 α , HIF3 α , stable during hypoxia and able to bind to HRE (hypoxic response elements) [43]. The role of PARP-1 in the interaction with HIF1 α and HIF2 α in the induction of their activity and stability has been evidenced. In hypoxic conditions, the oxidative stress induced by oxidative phosphorylation involves a hyperactivation of PARP-1 and consequently the stabilization of HIF1 α . HIF2 α is also capable of interacting with PARP-1. PARP-1 binds to the HIF2 α promoter affecting its transcription. HIF2 α is important both during tumorigenesis and in promoting tumor aggression and neovascularization. Any inhibition of PARP-1 will cause the reduction of the accumulation of HIF2 α in the hypoxic context and consequently all its functions will be compromised [43]. The limitation to the use of PARP inhibitors is related to the presence of resistance phenomena in tumors related to BRCA mutations. It appears that more than 100 genes are involved in the DNA repair pathway, and that BRCA-mutated cells are also HR-defective, due to other alterations. In recent years, PARP inhibitors (PARPi) have emerged as a promising class of chemotherapeutic agents for ovarian cancer associated with defects in homologous recombination DNA repair (HRR) system. Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an opportunity to optimise PARPi use in HGSC; however, methodologies are diverse and clinical application remains controversial [44]. In the case of cancer, anti-angiogenesis treatments are often used leading to block the formation of new

vessels, limiting the existing ones and sequestering essential elements (nutrients, oxygen and blood) from the tumor itself, thus blocking its growth. The use of angiogenesis inhibition associated with PARP-1 inhibitors has been approved by the FDA for some types of tumors. This association was found to be safe, as it does not generate cross-toxicities. In this context, the use of PARP inhibitors at full doses alone may be considered in the future.

mPGES-1 and PARP-1 inhibitors

mPGES-1 is present in low amounts in normal tissues and is induced upon inflammation, but it has been found overexpressed in several human cancers, including prostate, colon, lung, stomach, pancreas, cervix, breast, papillary thyroid carcinoma, head and neck squamous carcinoma, melanoma, and gliomas. mPGES-1 inhibitors have been recently reviewed for their potential activity as anticancer and antiinflammatory and cardioprotective [29]. New mPGES-1 inhibitors are under study [45,46]. Sonlicromanol is an oral drug recently discovered as selective mPGES-1 inhibitor that could affect prostate cancer cells-derived spheroid growth. Metabolites are often more active than the parent compound [47-49]. Actually, KH176m, the *in vivo* active metabolite of Sonlicromanol has been studied and suggested as more active than the parent compound thus being a potential novel treatment approach for cancer patients with high mPGES-1 expression [50]. Sorafenib, a multikinase inhibitor, initiated apoptosis by cleavage of caspases 3, 7 and PARP-1 [51-53]. mPGES-1 inhibitors have been also proposed as antifungals. mPGES-1 participated in various pathophysiological states in which both COX-1 and COX-2 are involved, implying that the role of the mPGES-1 enzyme is partially similar to that of COX. Currently, mPGES-1 inhibitors are emerging as the foremost agents in the treatment of inflammatory related diseases, but their antifungal activity is still not clear. Thus, the use of more selective mPGES-1 inhibitors as an alternative pharmacological approach to antifungals front as an alternative may be a wise treatment strategy [54]. Several compounds, including triclosan and many natural products, are considered to be mPGES-1 inhibitors, such as Myrtucommulone from myrtle, Arzanol from *Helichrysum*, and Curcumin, which

have anti-inflammatory and anti-carcinogenic properties [55,56]. There are currently no approved mPGES-1 inhibitors for clinical practice [29]. PARP-1 activation has been associated with many tumors and inflammation-related clinical conditions, including asthma, sepsis, arthritis, atherosclerosis, and neurodegenerative diseases, to name a few [57]. PARP-1 activity has been reported to make more contribution to cells death after ischemic stroke [58]. Recent evidence suggests that PARP-1 inhibitors may exert neuroprotection in the ischemic stroke [59], such as other neuroprotective agents [60,61]. PARP-1 inhibitors have been hypothesized to be involved in Alzheimer's disease (AD). Nicotinamide (vitamin B₃) is a key component in the cellular production of Nicotinamide Adenine Dinucleotide (NAD) and an inhibitor of PARP-1. Nicotinamide has been recently proposed as an adjunctive treatment for AD at early stages of the disease not only to increase NAD⁺ stores but as a PARP-1 inhibitor, raising the hypothesis that other PARP-1 inhibitors might be explored for the treatment of AD [62].

Conclusions

The novel therapeutic targets mPGES-1 and PARP may represent a promising strategy in the treatment of various types of cancer. Through the study of these targets, the mechanisms of proliferation and growth of neoplastic cells was better understood. PARP inhibitors limitation is the appearance of resistance phenomena in tumors related to BRCA mutations. The ideal strategy could be to first measure the complete genomic instability within a tumor by recording the loss of gene heterozygosity, any allelic changes or the presence of somatic mutations. This could allow a more accurate approach capable of detecting sensitivity to PARP inhibitors and thus improving drug treatment for patients. Screening for HRD is able to offer patients the opportunity to be treated with specific PARP inhibitors and further targeted therapies so as to have a greater weapon to counteract tumor progression. Drugs capable of inhibiting mPGES-1 are to be considered a powerful weapon to implement important future strategies for the treatment of cancer.

References

1. Sinicropi, M.S., Lappano, R., Caruso, A., Santolla, M. F., et al. (2015). (6-bromo-1,4-dimethyl-9H-carbazol-3-yl-methylene)-hydrazine (carbhydraz) acts as a GPER agonist in breast cancer cells. *Current Topics in Medicinal Chemistry*, 15(11), 1035-1042.
2. Sirignano, E., Satumino, C., Botta, A., Sinicropi, M. S., Caruso, A., Pisano, A., et al. (2013). Synthesis, characterization and cytotoxic activity on breast cancer cells of new half-titanocene derivatives. *Bioorganic & Medicinal Chemistry Letters*, 23(11), 3458-3462.
3. Rizza, P., Pellegrino, M., Caruso, A., Iacopetta, D., et al. (2016). 3-(Dipropylamino)-5-hydroxybenzofuro[2,3-f]quinazolin-1(2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progression. *European Journal of Medicinal Chemistry*, 107, 275-287.
4. Iacopetta, D., Catalano, A., Ceramella, J., Barbarossa, A., et al. (2020). Synthesis, anticancer and antioxidant properties of new indole and pyranoindole derivatives. *Bioorganic Chemistry*, 105, 104440.
5. Puxeddu, M., Shen, H., Bai, R., Coluccia, A., et al. (2021). Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia. *European Journal of Medicinal Chemistry*, 221, 113532.
6. Iacopetta, D., Carocci, A., Sinicropi, M. S., Catalano, A., et al. (2017). Old drug scaffold, new activity: thalidomide-correlated compounds exert different effects on breast cancer cell growth and progression. *ChemMedChem*, 12(5), 381-389.
7. Caruso, A., Voisin-Chiret, A. S., Lancelot, J. C., Sinicropi, M. S., Garofalo, A., Rault, S. (2008). Efficient and simple synthesis of 6-aryl-1, 4-dimethyl-9H-carbazoles. *Molecules*, 13(6), 1312-1320.
8. Sinicropi, M. S., Iacopetta, D., Rosano, C., Randino, R., et al. (2018). N-thioalkylcarbazoles derivatives as new anti-proliferative agents: Synthesis, characterisation and molecular mechanism evaluation. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 33(1), 434-444.
9. Iacopetta, D., Ceramella, J., Catalano, A., Satumino, C., et al. (2021). Schiff Bases: Interesting Scaffolds with Promising Antitumoral Properties. *Applied Sciences*, 11(4), 1877.
10. Caruso, A., Lancelot, J. C., El-Kashef, H., Sinicropi, M. S., Legay, R., Lesnard, A., Rault, S. (2009). A rapid and versatile synthesis of novel pyrimido [5, 4-b] carbazoles. *Tetrahedron*, 65(50), 10400-10405.
11. Tundis, R., Iacopetta, D., Sinicropi, M. S., Bonesi, M., et al. (2017). Assessment of antioxidant, antitumor and pro-apoptotic effects of *Salvia fruticosa* Mill. subsp. *thomasi* (Lacaita) Brullo, Guglielmo, Pavone & Terrasi (Lamiaceae). *Food and Chemical Toxicology*, 106, 155-164.
12. Fazio, A., Iacopetta, D., La Torre, C., Ceramella, J., et al. (2018). Finding solutions for agricultural wastes: Antioxidant and antitumor properties of pomegranate Akko peel extracts and β -glucan recovery. *Food & function*, 9(12), 6618-6631.
13. Iacopetta, D., Ceramella, J., Rosano, C., Mariconda, A., et al. (2021). N-Heterocyclic Carbene-Gold (I) Complexes Targeting Actin Polymerization. *Applied Sciences*, 11(12), 5626.
14. Iacopetta, D., Rosano, C., Sirignano, M., Mariconda, A., et al. (2020). Is the way to fight cancer paved with gold? Metal-based carbene complexes with multiple and fascinating biological features. *Pharmaceuticals*, 13(5), 91.
15. Bruno, G., Nicolò, F., Schiavo, S. L., Sinicropi, M. S., et al. (1995). Synthesis and spectroscopic properties of di-2-pyridyl sulfide (dps) compounds. Crystal structure of $[\text{Ru}(\text{dps})_2\text{Cl}_2]$. *Journal of the Chemical Society, Dalton Transactions*, (1), 17-24.
16. Iacopetta, D., Mariconda, A., Satumino, C., Caruso, A., et al. (2017). Novel gold and silver carbene complexes exert antitumor effects triggering the reactive oxygen species dependent intrinsic apoptotic pathway. *ChemMedChem*, 12(24), 2054-2065.
17. Ceramella, J., Mariconda, A., Iacopetta, D., Satumino, C., et al. (2020). From coins to cancer therapy: Gold, silver and copper complexes targeting human topoisomerases. *Bioorganic & Medicinal Chemistry Letters*, 30(3), 126905.
18. Catalano, A., Sinicropi, M. S., Iacopetta, D., Ceramella, J., et al. (2021). A review on the advancements in the field of metal complexes with Schiff bases as antiproliferative agents. *Applied Sciences*, 11(13), 6027.
19. van der Zanden, S. Y., Qiao, X., Neefjes, J. (2021). New insights into the activities and

toxicities of the old anticancer drug doxorubicin. *The FEBS Journal*, 288, 6095-6111.

20. Zahavi, D., Weiner, L. (2020). Monoclonal antibodies in cancer therapy. *Antibodies*, 9(3), 34.

21. Paesano, N., Marzocco, S., Vicidomini, C., Satumino, C., Autore, G., De Martino, G., Sbardella, G. (2005). Synthesis and biological evaluation of 3-benzyl-1-methyl- and 1-methyl-3-phenyl-isothioureas as potential inhibitors of iNOS. *Bioorganic & Medicinal Chemistry Letters*, 15(3), 539-543.

22. Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., et al. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. *Cancer Treatment Reviews*, 86, 102017.

23. Wright, M. D., Abraham, M. J. (2021). Preclinical discovery and development of abemaciclib used to treat breast cancer. *Expert Opinion on Drug Discovery*, 16(5), 485-496.

24. Siddiqui, M. A., Gollavilli, P. N., Ramesh, V., Parma, B., et al. (2021). Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. *British Journal of Cancer*, 124(1), 281-289.

25. Pozzi, C., Ferrari, S., Cortesi, D., Luciani, R., et al. (2012). The structure of *Enterococcus faecalis* thymidylate synthase provides clues about folate bacterial metabolism. *Acta Crystallographica Section D: Biological Crystallography*, 68(9), 1232-1241.

26. Parisi, O. I., Ruffo, M., Malivindi, R., Vattimo, A. F., et al. (2020). Molecularly imprinted polymers (MIPs) as theranostic systems for sunitinib controlled release and self-monitoring in cancer therapy. *Pharmaceutics*, 12(1), 41.

27. Andrikopoulou, A., Apostolidou, K., Chatzinikolaou, S., Bletsas, et al. (2021). Trastuzumab administration during pregnancy: an update. *BMC cancer*, 21(1), 1-12.

28. Sjögren, T., Nord, J., Ek, M., Johansson, P., et al. (2013). Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the MAPEG superfamily. *Proceedings of the National Academy of Sciences*, 110(10), 3806-3811.

29. Bergqvist, F., Morgenstern, R., Jakobsson, P. J. (2020). A review on mPGES-1 inhibitors: From preclinical studies to clinical applications.

Prostaglandins & Other Lipid Mediators, 147, 106383.

30. Smeitink, J.; Jiang, X.; Pecheritsyna, S.; Renkema, H.; van Maanen, R.; Beyrath, J. Hypothesis: mPGES-1-derived prostaglandin E2, a so far missing link in COVID-19 pathophysiology? *Preprints 2020*, 2020040180.

31. Catalano, A. (2020). COVID-19: Could Irisin Become the Handyman Myokine of the 21st Century. *Coronaviruses*, 1(1), 32-41.

32. Finelli, F., Bonomo, M. G., Giuzio, F., Capasso, A., et al. (2021). The nutritional role of vitamin D during the Sars Covid-19 pandemic. *Pharmacologyonline*, 259-261.

33. Miwa, M., Hanai, S., Yamashita, S., Tanaka, M., Uchida, K. (2020). *Drosophila melanogaster* as a model for understanding polyADP-ribosylation. *Frontiers in bioscience (Landmark edition)*, 25, 118-133.

34. Carrisi, C., Madeo, M., Morciano, P., Dolce, V., et al. (2008). Identification of the *Drosophila melanogaster* mitochondrial citrate carrier: bacterial expression, reconstitution, functional characterization and developmental distribution. *Journal of Biochemistry*, 144(3), 389-392.

35. Pascal, J. M. (2018). The comings and goings of PARP-1 in response to DNA damage. *DNA repair*, 71, 177-182.

36. Chang, H. H., Meillet, E. J. (2011). Identification and development of mPGES-1 inhibitors: where we are at?. *Future Medicinal Chemistry*, 3(15), 1909-1934.

37. Hammarberg, T., Hamberg, M., Wetterholm, A., Hansson, H., et al. (2009). Mutation of a critical arginine in microsomal prostaglandin E synthase-1 shifts the isomerase activity to a reductase activity that converts prostaglandin H2 into prostaglandin F2α. *Journal of Biological Chemistry*, 284(1), 301-305.

38. Brock, J. S., Hamberg, M., Balagunaseelan, N., Goodman, M., et al. (2016). A dynamic Asp-Arg interaction is essential for catalysis in microsomal prostaglandin E2 synthase. *Proceedings of the National Academy of Sciences*, 113(4), 972-977.

39. Jubin, T., Kadam, A., Jariwala, M., Bhatt, S., et al. (2016). The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. *Cell Proliferation*, 49(4), 421-437.

40. Yelamos, J., Farres, J., Llacuna, L., Ampurdanes, C., et al. (2011). PARP-1 and PARP-2: New players in tumour development. *American Journal of Cancer Research*, 1(3), 328.
41. Harrison, D., Gravells, P., Thompson, R., Bryant, H. E. (2020). Poly (ADP-Ribose) Glycohydrolase (PARG) vs. Poly (ADP-Ribose) Polymerase (PARP)—Function in Genome Maintenance and Relevance of Inhibitors for Anti-Cancer Therapy. *Frontiers in Molecular Biosciences*, 7, 191.
42. Citarelli, M., Teotia, S., Lamb, R. S. (2010). Evolutionary history of the poly (ADP-ribose) polymerase gene family in eukaryotes. *BMC Evolutionary Biology*, 10(1), 1-26.
43. Martí, J. M., Fernández-Cortés, M., Serrano-Sáenz, S., Zamudio-Martinez, E., Delgado-Bellido, D., Garcia-Diaz, A., Oliver, F. J. (2020). The multifactorial role of PARP-1 in tumor microenvironment. *Cancers*, 12(3), 739.
44. Miller, R. E., Leary, A., Scott, C. L., Serra, V., et al. (2020). ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. *Annals of Oncology*, 31(12), 1606-1622.
45. Erensoy, G., Ding, K., Zhan, C. G., Elmezayen, A. D., et al. (2020). Synthesis, in silico studies and cytotoxicity evaluation of novel 1, 3, 4-oxadiazole derivatives designed as potential mPGES-1 inhibitors. *Journal of Research in Pharmacy*, 24, 4, 436-451.
46. Shekfeh, S., Çalışkan, B., Fischer, K., Yalçın, T., et al. (2019). A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors. *ChemMedChem*, 14(2), 273-281.
47. Catalano, A., Desaphy, J. F., Lentini, G., Carocci, A., et al. (2012). Synthesis and toxicopharmacological evaluation of *m*-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels. *Journal of Medicinal Chemistry*, 55(3), 1418-1422.
48. Catalano, A., Carocci, A., Fracchiolla, G., Franchini, C., et al. (2004). Stereospecific synthesis of “*para*-hydroxymexiletine” and sodium channel blocking activity evaluation. *Chirality*, 16(2), 72-78.
49. De Bellis, M., De Luca, A., Rana, F., Cavalluzzi, M. M., et al. (2006). Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents. *British Journal of Pharmacology*, 149(3), 300-310.
50. Jiang, X., Renkema, H., Smeitink, J., Beyrath, J. (2021). Sonlicromanol’s active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth. *Plos one*, 16(7), e0254315.
51. Bonelli, M. A., Fumarola, C., Alfieri, R. R., La Monica, S., Cavazzoni, A., Galetti, M., et al. (2010). Synergistic activity of letrozole and sorafenib on breast cancer cells. *Breast Cancer Research and Treatment*, 124(1), 79-88.
52. Catalano, A., Iacopetta, D., Sinicropi, M. S., Franchini, C. (2021). Diarylureas as antitumor agents. *Applied Sciences*, 11(1), 374.
53. Catalano, A., Iacopetta, D., Pellegrino, M., Aquaro, S., Franchini, C., Sinicropi, M. S. (2021). Diarylureas: Repositioning from antitumor to antimicrobials or multi-target agents against new pandemics. *Antibiotics*, 10(1), 92.
54. Rosato, A., Catalano, A., Carocci, A., Carrieri, A., et al. (2016). In vitro interactions between anidulafungin and nonsteroidal anti-inflammatory drugs on biofilms of *Candida* spp. *Bioorganic & Medicinal Chemistry*, 24(5), 1002-1005.
55. Liu, X., Wang, D., Yu, C., Li, T., et al. (2016). Potential antifungal targets against a *Candida* biofilm based on an enzyme in the arachidonic acid cascade—A review. *Frontiers in Microbiology*, 7, 1925.
56. Iacopetta, D., Catalano, A., Ceramella, J., Satumino, C., et al. (2021). The Different Facets of Triclocarban: A Review. *Molecules*, 26(9), 2811.
57. Pazzaglia, S., Pioli, C. (2020). Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases. *Cells*, 9(1), 41.
58. Li, W. H., Yang, Y. L., Cheng, X., Liu, M., Zhang, S. S., Wang, Y. H., Du, G. H. (2020). Baicalein attenuates caspase-independent cells death via inhibiting PARP-1 activation and AIF nuclear translocation in cerebral ischemia/reperfusion rats. *Apoptosis*, 25(5), 354-369.
59. Chen, J., Li, X., Xu, S., Zhang, M., et al. (2020). Delayed PARP-1 inhibition alleviates post-stroke inflammation in male versus female mice:

differences and similarities. *Frontiers in Cellular Neuroscience*, 14, 77.

60. Gandolfo, C., Sandercock, P. A., Conti, M. (2002). Lubeluzole for acute ischaemic stroke. *Cochrane Database of Systematic Reviews*, Doi: <https://doi.org/10.1002/14651858.CD001924>.

61. Bruno, C., Carocci, A., Catalano, A., Cavalluzzi, M. M., et al. (2006). Facile, alternative route to lubeluzole, its enantiomer, and the racemate. *Chirality*, 18(4), 227-231.

62. Salech, F., Ponce, D. P., Paula-Lima, A. C., SanMartin, C. D., Behrens, M. I. (2020). Nicotinamide, a poly [ADP-ribose] polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer's disease. *Frontiers in Aging Neuroscience*, 12, 255.




Figure 1. Central cavity and active site in mPGES-1. (A) Surface representation of the active site and the central cavity show Arg73 in the GSH coordinating conformation. (B) The same as for (A) but with Arg73 in the monomer interaction conformation. (C) View of both Arg73 conformations from the luminal side highlighting the potential for cross-talk between the monomers. GSH and a short stretch of helix II is shown for each monomer in blue, yellow, and green, respectively.




Figure 2. Suggested mechanisms for PGE₂ synthase activity of mPGES-1 mutant ($G-S^-$ = glutathione thiolate).